

07-06-09

YFW

Express Mail No.: EL615431825US

Mailed: July 2, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Gerhard MAASS, et al.

Application No.: 10/688,120

Filed: October 16, 2003

For: ADENO-ASSOCIATED VIRUS VECTOR
FOR BOOSTING IMMUNOGENICITY
OF CELLS

Art Unit: 1646

Examiner: Not Yet Assigned

Confirmation No.: 9237

Attorney Docket: 00687.0002.CPUS03

Information Disclosure Statement

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☐ 1. This Information Disclosure Statement is being filed;
 - ☐ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☒ c. Before the mailing date of a first Office Action on the merits;
 - ☐ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- ☐ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or

- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
- ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.


- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- 8. Copies of the documents were cited by or submitted to the Office in Application No. 09/142,443, filed May 5, 1999, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 00687.0002.CPUS03.

Respectfully submitted,

Date: July 2, 2004



Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
Telephone: (650) 463-8181
Facsimile: (650) 463-8400

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTORNEY DOCKET NO.

00687.0002.CPUS03

APPLICATION NO.

10/688,120

APPLICANT

Gergard MAASS, et al.

FILING DATE

October 16, 2003

GROUP

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 94/21808	09/29/94	PCT				
	2.	WO 95/14101	05/26/95	PCT				
	3.	WO 95/14771	06/01/95	PCT				
	4.	WO 95/27494	10/19/95	PCT				

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	5.	Hallek, M. et al., "Human Lymphoid Tumor Cells Transduced With Recombinant Adeno-Associated Virus (Aav) Vectors Containing B7-1 And B7-2 Genes Provide Potent Costimulatory Signal For T-Cell Proliferation", <i>Blood</i> 86(10): (Supp1)1995
	6.	Shaughnessy et al., "Parvoviral Vectors For The Gene Therapy Of Cancer", <i>Seminars in Oncology</i> , 23(1):159-171 (1996)
	7.	Wendtner, C.M. et al., "Human Lymphoma Cells Transduced With Recombinant Adeno-Associated Virus (AAV) Vectors Containing B7-1 and B7-2 Genes Provide Potent Costimulatory Signal For T-cell Proliferation", <i>Oncology</i> 18: (Supp2) 32 (1995)
	8.	Wendtner, C.M. et al., Efficient, Stable And Functional Expression Of Costimulatory Molecules Of B7-1 (CD80) And B7-2 (CD86) In Human Lymphoma Cells By An Improved Adeno-Associated Virus (AAV) Vector", <i>Journal of Molecular Medicine</i> 73(4): B13-B14 (1995)
	9.	Zhang et al., "Gene Therapy With An Adeno-Associated Virus Carrying An Interferon Gene Results In Tumor Growth Suppression And Regression", <i>Cancer Gene Therapy</i> 3(1):31-38 (1996)
EXAMINER		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.